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Introduction
 Basal Cell Carcinoma is the most common type of 
skin cancer and probably one of the most common cancers 
in the world. BCC is well known for its slow growing 
feature within the epidermis of skin (Moad et al., 2012). 
BCC is locally invasive and rarely metastatic with a high 
rate of recurrence. Why does BCC rarely metastasize in 
comparison with other skin cancers such as Melanoma and 
Squamous Cell Carcinoma (SCC)? The Hedgehog (Hh) 
pathway has been proven to be involved in pathogenesis 
of BCC, but this pathway cannot solely explain metastatic 
inefficiency and restriction to local invasion (Schwartz 
and Pirrotta, 2007). Many studies have been conducted on 
molecular causes of cancer metastasis and have revealed 
certain transcription factors which act in Epithelial 
Mesenchymal Transition (EMT) pathway such as TWIST1, 
SNAIL and SNAI2 (Zhu et al., 2013). In EMT, epithelial 
cells undergo transition into mesenchymal phenotype and 
are believed to play a critical role in aggressiveness and 
metastasis (Zhu et al., 2013). Most EMT related molecules 
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show up-regulation in metastatic cancer and have been 
investigated especially in SCC (Mikheeva et al., 2010; 
Guo et al., 2012; Yang et al., 2010; Reinisch et al., 2007; 
Mihic et al., 2007; Gao et al., 2013; Wang et al., 2013)). 
Since BCC rarely metastasizes, it can be a proper model to 
study the inhibitory mechanisms of metastasis. Therefore, 
we decided to test the expression of transcription factors 
which have been demonstrated to have a major role in 
aggressiveness of other skin cancers.
 SNAI2 and TWIST1 cooperatively with BMI1 are 
demonstrated to be the important transcription factors 
in EMT and most of these transcription factors regulate 
each other. BMI1 (B lymphoma Mo-MLV insertion region 
1 homolog) is a component of the polycomb repressive 
complex 1 which epigenetically silences genes (Vander 
et al., 1994). BMI1 was first identified as an oncogene in 
mouse lymphomas (Yang et al., 2010; Casas et al., 2011). 
It has a role in proliferation and self-renewal (Vander et 
al., 1994). BMI1 expression has been demonstrated to 
be regulated by TWIST1 in Squamous Cell Carcinoma 
(SCC) cell lines (Guo et al., 2011). It was shown that 
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BMI1 and TWIST1 cooperatively silence the E-cadherin 
locus which is a marker of epithelial cells (Guo et al., 
2011). TWIST1 also regulates SNAI2/SLUG (Yang et al., 
2004). Interestingly, it has been proven that SNAI2 is 
essential for TWIST1 function (Yang et al., 2004). The 
BMI1-TWIST1-SNAI2 axis has a role in EMT (Mihic et al., 
2007; Reinisch et al., 2007; Mikheeva et al., 2010; Yang 
et al., 2010; Guo et al., 2012). The significance of this 
axis in Basal Cell Carcinoma (BCC) was not previously 
explored though there is one study, to the best of our 
knowledge, documenting elevated BMI1 expression via 
immunostaining in sixteen BCC cases (Bachmann et al., 
2008). In two separate studies, expression of BMI1 in 
Melanoma was reported with conflicting results, but ample 
evidence provides strong support for BMI1 involvement 
in endowment of aggressive behavior to cancerous 
cells. Recently, one study demonstrated use of BMI1 
expression in identification of Merkel Cell Carcinoma 
(MCC) subtypes, a rare and highly aggressive skin cancer 
(Kouzmina et al., 2012). However, mRNA expression 
level of BMI1, TWIST1, and SNAI2 was not previously 
quantitated in a large group of BCC cases in comparison 
with normal skin. 
 Since BCC rarely metastasizes and is one of the least 
dangerous cancers in the world, we hypothesized BCC 
would be a good model system to elucidate mechanisms 
which inhibit processes that drive tumor metastasis. 
The aim of this pilot study was to examine the mRNA 
expression level of BMI1, TWIST1 and SNAI2/SLUG in 
basal cell carcinoma to generate a more complete picture 
of these genes in a non-metastatic and non-aggressive 
cancer.
 
Materials and Methods
Patients
 We collected thirty-five fresh tissue samples from 
individuals diagnosed with basal cell carcinoma in 2010 at 
the Tumor Clinic and Reconstructive Surgery Center of the 
Razi Dermatology Hospital, Tehran, Iran. The procedures 
followed were in accordance with the ethical standards of 
Tehran University of Medical Sciences and the Helsinki 
Declaration of 1975, as revised in 1983. Our collection of 
BCC cases included twelve cases of nodular, four cases of 
superficial, five cases of infiltrative, nine cases of micro-
nodular, three cases of meta-typical and two cases of the 
basosquamous type tumor. The thirty-five BCC cases 
contained twenty-eight males and seven females with an 
average age of 65±2. Seven fresh normal skin tissues were 
obtained from cosmetic surgeries such as face lifts. All 
cases were reviewed by a dermatopathologist to confirm 
the diagnosis and the subclassification. 
Real-time RT-PCR
 RNA was extracted from tissue samples using the 
Tripure isolation reagent (Roche, Mannheim, Germany) 
according to the manufacturer’s instructions. cDNA 
synthesis was performed using the PrimeScript RT 
reagent (Takara Bio Inc, Shiga, Japan) according to the 
manufacturer’s protocols. For expression analysis, primers 
were designed using the NCBI. Primer-design tool (Table 
1). Quantitative Real-time PCR was carried out using 
the SYBR Premix Ex Taq TM (Takara Bio Inc, Shiga, 
Japan) on rotor gene 6,000 corbette detection system.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
gene expression was used as a housekeeping gene for 
normalization of data. All experiments were performed 
in duplicates.
Statistical analysis
 Statistical analysis was performed using the SPSS 
statistical package (SPSS, Chicago, IL, U.S.A.). The 
statistical importance of differences was assessed using 
the χ2 test. p values less than 0.05 were considered as 
statistically significant. The specificity and sensitivity 
of data was determined by the Receiver Operating 
Characteristic (ROC) curve.
Results 
 Mean Relative Expression (MRE) of all samples is 
reported in Figure 1. BCC samples were divided into 
two groups based on invasive and aggressive behavior 
as evaluated by a dermatopathologist; highly invasive 
subtypes were included in the high risk group (micro-
nodular, infiltrative and meta-typical) and the remaining 
subtypes were included in the low risk group. Although 
BMI1 and TWIST1 mRNA expression decreased in BCC 
samples compared to controls (p<0.00l and p=0.00l, 
respectively), there seems to be no significant BMI1, 
TWIST1 and SNAI2 MRE difference between high risk 
and low risk BCC groups. SNAI2 expression did not 
demonstrate a significant difference between BCC and 
controls. Expression pattern of BMI1 and TWIST1 seems 
to be corroborative and in line with previous studies 
demonstrating TWIST1 regulation of BMI1.
 The ROC curve was used to assess the sensitivity and 
	  Figure 1. Mean Relative Expression (MRE) of 
TWIST1, BMI1 and SNAI2 in High Risk BCC, Low 
Risk BCC and Controls
Table 1. Primer Sequence of BMI1, TWIST1, and 
SNAI2 for Real-time PCR
Target genes Sequence (5`- 3`)             Product length (bp) 
TWIST1 F: GGCCGGAGACCTAGATG   187
(NM_000474.3)  R: ACGGGCCTGTCTCGCTTTCT
BMI1 F: CTGGTTGCCCATTGACAGCG    145
(NM_005180.8) R:AAATCCCGGAAAGAGCAGCC 
SNAI2 F: GACACATTAGAACTCACACGGG 200
(NM_003068.4)  R: GTGTGCTACACAGCAGCCAG 
GAPDH  F: GGTCGGAGTCAACGGATTTG  180
(NM_002046.4)  R: CCGTTCTCAGCCTTGACGGT 
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the specificity of TWIST1 and BMI1. BMI1 can strongly 
differentiate control from BCC with 100 % specificity and 
94% sensitivity (Table 2). In addition, TWIST1 with 94% 
sensitivity, has a lower specificity of 80% in comparison 
with BMI1.
Discussion
Primary tumors are responsible for 10% of deaths 
but metastases are responsible for 90% of cancer 
deaths. BMI1, as a stemness marker, and TWIST1, as a 
mesenchymal marker, have been implicated in aggressive 
behavior of cancers. Stemness markers and mesenchymal 
markers are involved in Epithelia-Mesenchymal 
Transition which occurs in cancer metastasis. Strong 
evidence has established a positive association between 
BMI1 and TWIST1 expression and metastatic cancers such 
as metastatic skin cancers. On the flip-side of the coin is 
Basal Cell Carcinoma (BCC), well known as one of the 
least aggressive cancers in the world. BCC is also a rare 
example of cancers which rarely metastasize. Thus, BCC 
provides a unique natural human model to monopolize in 
trying to understand regulatory steps involved in cancer 
metastasis prevention. We hypothesized BCC could be a 
good model system to elucidate mechanisms which inhibit 
processes that drive tumor metastasis.
The results confirm the study hypothesis. A stemness 
marker, BMI1, and a mesenchymal marker, TWIST1, 
clearly shown to be up-regulated in aggressive cancers are 
shown to be down-regulated in Basal Cell Carcinoma, our 
proposed model for studying natural intrinsic inhibitory 
metastatic steps utilized in non-aggressive cancers. 
The initial utility of these results in clinical settings 
could be that down-regulation of BMI1 and TWIST1 
mRNA could forecast metastatic inefficiency status of a 
patient and could be used for follow-up purposes. Further 
biochemical studies on signaling pathways involving 
and connected to BMI1 and TWIST1 could provide more 
details to the molecular mechanism of cancer metastasis 
responsible for 90% of cancer deaths.
TWIST1 which is a major mesenchymal mediator, 
with BMI1, a stemness molecule, cooperatively have an 
important role in EMT none of our BCC tumor samples 
were metastatic, but previous studies have demonstrated 
BMI1, TWIST1 and SNAI2 up-regulation in aggressive 
SCC (Patel et al., 2007; Yang et al., 2010), SNAI2 up-
regulation in melanoma patient tumor samples (Shirley 
et al., 2012), and TWIST1 up-regulation in one case of 
metastatic BCC (Majima et al., 2012). In the present study, 
BMI1 and TWIST1 demonstrate marked down-regulation 
whereas SNAI2 expression shows no significant change 
in BCC tumors compared to controls. The limited data 
generated in this small group of BCC cases demonstrates 
BMI1 and TWIST1 dichotomy of action in locally invasive 
BCC in contrast to metastatic BCC, aggressive SCC, and 
melanoma. Local invasion and metastatic inefficiency of 
BCC shows no correlation with SNAI2.
BMI1 is a potential mediator of BCC carcinogenesis 
downstream the Hedgehog signaling pathway 
demonstrating down-regulation in the present study of 
non-metastatic BCC cases (Vander et al., 1994). It seems 
that BMI1 up-regulation has a role in aggressive behavior 
of metastatic cancerous cells. In the present study, with 
a small sample of non-metastatic, slow growing BCC 
cases, BMI1 and TWIST1 cooperatively demonstrate 
down-regulation. This may provide a clue for molecular 
differentiation between metastatic and non-metastatic 
cancerous cells, as perfectly illustrated for MCC subtyping 
via BMI1 expression (Kouzmina et al., 2012). However, 
more studies need to clarify these findings. 
Our results suggest BMI1 as a potential biomarker 
for distinguishing controls from BCC tumor samples. 
The BMI1-TWIST1-SNAI2 axis we initially proposed 
was confirmed in this pilot study with limited number of 
cases, but further studies need to be conducted on greater 
number of BCC cases including metastatic BCC alongside 
SCC and melanoma cases. It may be a possibility that 
suppressed or elevated BMI1 and TWIST1 expression 
can distinguish locally invasive behavior from metastatic 
behavior. In conclusion, we have shown decreased BMI1 
and TWIST1 mRNA expression level in non-metastatic 
BCC tissue samples in comparison with normal skin 
tissue samples. SNAI2 mRNA expression did not show 
significant change in BCC compared with controls.
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